Korsana Biosciences, Inc. (KRSA)
31.65
+0.37
(+1.18%)
USD |
NASDAQ |
Nov 13, 16:00
Korsana Biosciences Enterprise Value : 1.011B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 1.011B |
| November 12, 2026 | 994.55M |
| November 11, 2026 | 1.020B |
| November 10, 2026 | 986.81M |
| November 09, 2026 | 989.54M |
| November 06, 2026 | 984.07M |
| November 05, 2026 | 955.84M |
| November 04, 2026 | 961.76M |
| November 03, 2026 | 1.026B |
| November 02, 2026 | 1.012B |
| October 30, 2026 | 942.63M |
| October 29, 2026 | 946.28M |
| October 28, 2026 | 941.27M |
| October 27, 2026 | 939.44M |
| October 26, 2026 | 1.031B |
| October 23, 2026 | 995.92M |
| October 22, 2026 | 1.092B |
| October 21, 2026 | 1.052B |
| October 20, 2026 | 983.16M |
| October 19, 2026 | 1.000B |
| October 16, 2026 | 1.045B |
| October 15, 2026 | 1.102B |
| October 14, 2026 | 1.133B |
| October 13, 2026 | 1.012B |
| October 12, 2026 | 1.120B |
| Date | Value |
|---|---|
| October 09, 2026 | 1.115B |
| October 08, 2026 | 1.096B |
| October 07, 2026 | 1.011B |
| October 06, 2026 | 1.017B |
| October 05, 2026 | 969.05M |
| October 02, 2026 | 958.57M |
| October 01, 2026 | 990.91M |
| September 30, 2026 | 1.027B |
| September 29, 2026 | 19.28M |
| September 28, 2026 | 17.35M |
| September 25, 2026 | 17.46M |
| September 24, 2026 | 21.22M |
| September 23, 2026 | 18.25M |
| September 22, 2026 | 19.88M |
| September 21, 2026 | 18.80M |
| September 18, 2026 | 19.88M |
| September 17, 2026 | 19.11M |
| September 16, 2026 | 17.60M |
| September 15, 2026 | 18.11M |
| September 14, 2026 | 17.83M |
| September 11, 2026 | 18.01M |
| September 10, 2026 | 13.54M |
| September 09, 2026 | 14.54M |
| September 08, 2026 | 12.91M |
| September 04, 2026 | 16.70M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Q32 Bio, Inc. | -24.10M |
| IRulya Therapeutics, Inc. | 79.05M |
| Climb Bio, Inc. | 393.71M |
| PepGen Inc. | 212.78M |
| Bridgebio Oncology Therapeutics, Inc. | -19.79M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -46.42M |
| Total Expenses (Quarterly) | 46.42M |
| EPS Diluted (Quarterly) | -3.432 |
| Earnings Yield | -41.31% |
| Normalized Earnings Yield | -41.31 |